Europe Pancreatic Cancer Diagnostics Market, By Test Type (Imaging Test, Biopsy, Blood Test, Genomic Test, and Others), Cancer Stage (Stage 0, Stage I, Stage II, Stage III and Stage IV), Tumor Type (Exocrine Tumors and Neuroendocrine Tumors), Product (Instrument-Based Products, Platform-Based Products, Kits and Reagents, and Other Consumables), Technology (Fluorescent In Situ Hybridization, Next Generation Sequencing, Fluoroimmunoassay, Comparative Genomic Hybridization, Immunohistochemical, and Others), Application (Screening, Diagnostic and Predictive, Prognostic, and Research), End User (Hospitals, Diagnostic Centers, Cancer Research Centers, Academic Institutes, Ambulatory Surgical Centers, and Others), Distribution Channel (Direct Tender, Retail Sales and Others), Industry Trends and Forecast to 2030.
Europe Pancreatic Cancer Diagnostics Market Analysis and Insights
The growing prevalence of pancreatic cancer as well as increasing need for diagnostic products for these conditions have enhanced the market demand. The advancement in technology for easy supply of products and fast manufacturing facilities are also attributing in the growth of the market. The major market players are highly focusing on product launches and product approvals during this crucial period. In addition, the government and regulatory bodies are supporting market players by product approval due to surging emergence.
The Europe pancreatic cancer diagnostics market is expected to grow in the forecast year due to the rise in market players and the availability of advanced services. Along with this, manufacturers are engaged in R&D activity for launching novel services in the market. The increasing research in the field of leukemia diagnosis and development is expected to further boost the market growth. However, difficulties in leukemia screening techniques is expected to hamper the growth of the Europe pancreatic cancer diagnostics market in the forecast period. Increasing healthcare expenditure on cancer diagnosis and treatment is expected to give opportunities to the market to enhance the treatment. The improvement in awareness about regular healthcare checkups, upcoming diagnostic centers and advancements in diagnostic methods for pancreatic cancer and technological developments is expected to boost the market’s growth. However, the high cost of testing and strict regulations and standards for the approval and commercialization of cancer diagnostic products and instruments is expected to challenge market growth.
La croissance de la population gériatrique, les initiatives stratégiques des acteurs du marché et du gouvernement, ainsi que l'augmentation des dépenses de santé offrent au marché des opportunités d'améliorer le traitement. Cependant, le manque de professionnels qualifiés et les cadres réglementaires stricts constituent des défis majeurs pour la croissance du marché. Cependant, le coût élevé des appareils et des traitements devrait freiner la croissance du marché européen du diagnostic du cancer du pancréas.
Le marché européen du diagnostic du cancer du pancréas est favorable et vise à réduire la maladie, améliorant ainsi la récupération et les performances des individus. Data Bridge Market Research analyse que le marché européen du diagnostic du cancer du pancréas connaîtra une croissance de 7,6 % au cours de la période de prévision de 2023 à 2030.
|
Rapport métrique |
Détails |
|
Période de prévision |
2023 à 2030 |
|
Année de base |
2022 |
|
Années historiques |
2021 (personnalisable pour 2020-2016) |
|
Unités quantitatives |
Chiffre d'affaires en millions USD, prix en USD |
|
Segments couverts |
Par type de test (test d'imagerie, biopsie, test sanguin, test génomique et autres), stade du cancer (stade 0, stade I, stade II, stade III et stade IV), type de tumeur (tumeurs exocrines et tumeurs neuroendocrines ), produit (produits basés sur des instruments, produits basés sur une plateforme, kits et réactifs et autres consommables), technologie (hybridation in situ fluorescente, séquençage de nouvelle génération, fluoroimmuno-essai, hybridation génomique comparative, immunohistochimique et autres), application (dépistage, diagnostic et prédictif, pronostic et recherche), utilisateur final (hôpitaux, centres de diagnostic, centres de recherche sur le cancer, instituts universitaires, centres de chirurgie ambulatoire et autres), canal de distribution (appel d'offres direct, vente au détail et autres). |
|
Pays couverts |
Allemagne, Royaume-Uni, France, Italie, Espagne, Russie, Pays-Bas, Suisse, Belgique, Turquie, Pologne, Suède, Norvège, Danemark, Finlande, Reste de l'Europe. |
|
Acteurs du marché couverts |
Siemens Healthcare Private Limited, Koninklijke Philips NV, FUJIFILM Corporation, Grail, Laboratory Corporation of America Holdings, DiaSource, Abbott, Agilent Technologies, Inc., Lee Biosolutions, Inc, MP BIOMEDICALS, Setia Scientific Solution, Boditech Med Inc., AccuBioTech Co., Ltd., Thermo Fisher Scientific, Creative Biolabs, Myriad Genetics, Inc., BD, CANON MEDICAL SYSTEMS CORPORATION, QIAGEN, Meridian Life Science, Inc., CTK Biotech, Inc., entre autres |
Définition du marché
Le cancer du pancréas est mortel et le processus de diagnostic du cancer du pancréas présente également des problèmes de sécurité et n'est pas rentable. L'un des troubles médicaux les plus coûteux à traiter en Europe est le cancer. Les patients atteints de cancer peuvent être hospitalisés et recevoir diverses thérapies pour la tumeur, telles que la chirurgie, la radiothérapie et la thérapie systémique. Les primes d'assurance maladie pour les patients atteints de cancer sont désormais plus chères que par le passé. De plus, leurs frais de participation aux frais, de franchise et de coassurance augmentent. Le diagnostic du cancer du pancréas comprend des échographies, des biopsies et des analyses sanguines. Le cancer du pancréas est l'une des principales causes de décès dans le monde et la prévalence de cette maladie a augmenté à un rythme alarmant.
Dynamique du marché européen du diagnostic du cancer du pancréas
Cette section traite de la compréhension des moteurs, des opportunités, des contraintes et des défis du marché. Tous ces éléments sont abordés en détail ci-dessous :
Conducteurs
- Augmentation de la prévalence du cancer du pancréas
Ce type de cancer peut toucher des personnes de tous âges. Il peut être difficile à diagnostiquer car, malgré sa large gamme de signes et de symptômes, ils ne sont pas spécifiques et peuvent être liés à d'autres pathologies plus répandues. Le cancer du pancréas est le huitième cancer le plus fréquent chez les femmes et le dixième cancer le plus fréquent chez les hommes. Les taux d'incidence du cancer du pancréas ont augmenté d'environ 1 % chaque année. Il survient moins fréquemment. Il est légèrement plus fréquent chez les femmes que chez les hommes, mais le risque moyen de développer un cancer du pancréas au cours de la vie chez les deux sexes est d'environ 0,5 % en moyenne. Ces pathologies comprennent : des douleurs abdominales, une perte d'appétit ou une perte de poids involontaire, un jaunissement de la peau et du blanc des yeux (jaunisse), des selles claires, des urines foncées et des démangeaisons cutanées. Il s'agit du huitième type de cancer le plus fréquemment diagnostiqué chez les adultes et les enfants, mais la plupart des cas surviennent chez les adultes. Bien qu'il puisse être diagnostiqué à tout âge, il est rare avant 45 ans. L'âge moyen du diagnostic est de 68 ans.
En raison de divers facteurs de risque, l'incidence du cancer du pancréas est en hausse en Europe, devenant un problème socio-économique majeur. Cela devrait agir comme un moteur sur le marché européen du diagnostic du cancer du pancréas.
- De nouvelles avancées technologiques dans le diagnostic du pancréas
Le cancer du pancréas est rarement détecté à un stade précoce, lorsqu'il est le plus facilement curable. En effet, il n'entraîne souvent aucun symptôme avant de s'être propagé à d'autres organes. Les spécialistes doivent diagnostiquer manuellement les cellules cancéreuses et non cancéreuses en examinant les images cellulaires au microscope et en les annotant. Cependant, cet examen microscopique manuel prend du temps et peut donner un diagnostic erroné. Le risque de prescrire des médicaments inappropriés a alors été réduit grâce à un logiciel informatisé. La création d'un système de classification automatique et fiable est devenue essentielle pour mettre fin aux effets dévastateurs de la maladie du pancréas. Les techniques de segmentation multiples constituent la base des algorithmes de classification du cancer du pancréas existants.
Opportunité
- Augmentation des dépenses de santé pour le diagnostic et le traitement du cancer
Partout dans le monde, les activités de recherche et développement augmentent en raison des dépenses de santé publique et des performances économiques. Alors que le secteur de la santé se classe au deuxième rang parmi tous les secteurs en ce qui concerne le montant dépensé pour les soins de santé, l'augmentation des dépenses de santé peut entraîner une meilleure offre d'opportunités de recherche et développement. On s'attend à ce qu'elle augmente la demande de diagnostics du cancer du pancréas. L'augmentation des dépenses de santé pour le traitement du cancer du pancréas aide également le patient à obtenir des diagnostics et des traitements avancés sans tracas pour une guérison rapide. Les dépenses de santé sont constituées de la combinaison des paiements directs (les personnes paient pour leurs soins), des dépenses gouvernementales et des sources. Cela comprend également l'assurance maladie et les activités des organisations non gouvernementales. Cette augmentation des dépenses de santé pour le traitement du cancer est une opportunité pour la demande du marché.
Retenue/Défi
- Diagnostic tardif et mauvais pronostic du cancer du pancréas
Le diagnostic tardif de la maladie est dû à l’augmentation du nombre de tumeurs cancéreuses du pancréas qui ne répondent pas aussi bien aux thérapies anticancéreuses couramment utilisées que d’autres types de cancer moins mortels. Il existe néanmoins des options de traitement, notamment la chirurgie, la chimiothérapie et la radiothérapie. Il existe différents types de cancer du pancréas. La plupart des cancers du pancréas sont de type exocrine. Cela signifie qu’ils commencent dans les cellules qui produisent les sucs digestifs pancréatiques. Environ 30 % des patients sont fumeurs et 5 % ont des antécédents de pancréatite, une inflammation du pancréas qui peut être provoquée par des calculs ou une forte consommation d’alcool.
Impact de la pandémie de COVID-19 sur le marché européen du diagnostic du cancer du pancréas
La COVID-19 a eu un impact négatif sur la croissance du marché, car les patients souffrant d'un cancer du pancréas ont reporté leur intervention chirurgicale en raison de l'augmentation rapide des cas de COVID-19 dans toutes les régions du monde. De plus, les personnes atteintes d'un cancer du pancréas risquaient de tomber gravement malades. La peur de l'infection par le coronavirus a affecté la croissance du marché du diagnostic du cancer du pancréas en pleine pandémie.
Développements récents
- En décembre 2022, FUJIFILM Holdings America Corporation a annoncé que la société avait conclu un accord d'achat d'actifs avec Inspirata, Inc. pour acquérir une activité de pathologie numérique afin d'élargir son offre d'imagerie d'entreprise robuste. Cela permet l'intégration d'images et de données de pathologie dans le système de dossiers médicaux électroniques d'un établissement de santé afin de rationaliser la prestation de soins pour les patients atteints de cancer.
- En août 2020, Siemens Healthcare GmbH a annoncé avoir conclu un accord avec Varian Medical Systems, Inc. Avec cette acquisition, Siemens Healthcare a contribué au développement de solutions avancées pour traiter le cancer et renforcer sa position dans le secteur de la santé.
Portée du marché européen du diagnostic du cancer du pancréas
Le marché européen du diagnostic du cancer du pancréas est classé en huit segments notables en fonction du type de test, des stades du cancer, du type de tumeur, du produit, de l'application, de la technologie, de l'utilisateur final et du canal de distribution. La croissance entre les segments vous aide à analyser les niches de croissance et les stratégies pour aborder le marché et déterminer vos principaux domaines d'application et la différence dans vos marchés cibles.
Type de test
- Test d'imagerie
- Biopsie
- Analyse de sang
- Test génomique
- Autres
Sur la base du type de test, le marché européen du diagnostic du cancer du pancréas est segmenté en test d'imagerie, biopsie, test sanguin, test génomique et autres.
Stade du cancer
- Étape 0
- Étape I
- Stade II
- Stade III
- Stade IV
Sur la base du stade du cancer, le marché européen du diagnostic du cancer du pancréas est segmenté en stade 0, stade I, stade II, stade III et stade IV.
Type de tumeur
- Tumeurs exocrines
- Tumeurs neuroendocrines
Sur la base du type de tumeur, le marché européen du diagnostic du cancer du pancréas est segmenté en tumeurs exocrines et tumeurs neuroendocrines.
Produit
- Produits basés sur des instruments
- Produits basés sur une plateforme
- Kits et réactifs
- Autres consommables
Sur la base du produit, le marché européen du diagnostic du cancer du pancréas est segmenté en produits basés sur des instruments, produits basés sur des plateformes, kits et réactifs et autres consommables.
Application
- Dépistage
- Diagnostic et prédictif
- Pronostic
- Recherche
Sur la base des applications, le marché européen du diagnostic du cancer du pancréas est segmenté en dépistage, diagnostic et prédictif, pronostic et recherche.
Technologie
- Hybridation in situ fluorescente
- Séquençage de nouvelle génération
- Dosage fluoro-immunologique
- Hybridation génomique comparative
- Immunohistochimique
- Autres
Sur la base de la technologie, le marché européen du diagnostic du cancer du pancréas est segmenté en hybridation fluorescente in situ, séquençage de nouvelle génération, fluoroimmuno-essai, hybridation génomique comparative, immunohistochimie et autres.
Utilisateur final
- Hôpitaux
- Centres de diagnostic
- Centres de recherche sur le cancer
- Instituts universitaires
- Centres de chirurgie ambulatoire
- Autres
Sur la base de l'utilisateur final, le marché européen du diagnostic du cancer du pancréas est segmenté en hôpitaux, centres de diagnostic, centres de recherche sur le cancer, instituts universitaires, centres de chirurgie ambulatoire et autres.
Canal de distribution
- Appel d'offres direct
- Ventes au détail
- Autres
Sur la base du canal de distribution, le marché européen du diagnostic du cancer du pancréas est segmenté en appels d'offres directs, ventes au détail et autres.
Analyse/perspectives du marché européen du diagnostic du cancer du pancréas
Le marché européen du diagnostic du cancer du pancréas est analysé et des informations et tendances sur la taille du marché sont fournies par pays, type de test, stades du cancer, type de tumeur, produit, application, technologie, utilisateur final et canal de distribution comme référencé ci-dessus.
En 2023, le marché allemand du diagnostic du cancer du pancréas devrait croître en raison de l’augmentation de la prévalence et de l’incidence du cancer du pancréas et de la sensibilisation accrue aux diagnostics du cancer du pancréas. Ce sont les principaux facteurs qui devraient stimuler la croissance du marché dans le pays.
La section par pays du rapport fournit également des facteurs individuels ayant un impact sur le marché et des changements dans la réglementation du marché qui ont un impact sur les tendances actuelles et futures du marché. Des points de données tels que l'analyse de la chaîne de valeur en aval et en amont, les tendances techniques, l'analyse des cinq forces du porteur et les études de cas sont quelques-uns des indicateurs utilisés pour prévoir le scénario de marché pour chaque pays. En outre, la présence et la disponibilité des marques et les défis auxquels elles sont confrontées en raison de la concurrence importante ou rare des marques locales et nationales, ainsi que l'impact des tarifs nationaux et des routes commerciales sont pris en compte lors de l'analyse prévisionnelle des données nationales.
Analyse du paysage concurrentiel et des parts de marché du diagnostic du cancer du pancréas en Europe
Le paysage concurrentiel du marché européen du diagnostic du cancer du pancréas fournit des détails par concurrents. Les détails inclus sont la présentation de l'entreprise, les finances de l'entreprise, les revenus générés, le potentiel du marché, les investissements dans la recherche et le développement, les nouvelles initiatives du marché, la présence, les sites et installations de production, les capacités de production, les forces et les faiblesses de l'entreprise, le lancement du produit, la largeur et l'étendue du produit et la domination des applications. Les points de données ci-dessus fournis ne concernent que l'orientation de l'entreprise sur le marché européen du diagnostic du cancer du pancréas.
Français Certains des principaux acteurs opérant sur le marché sont Siemens Healthcare Private Limited, Koninklijke Philips NV, FUJIFILM Corporation, Grail, Laboratory Corporation of America Holdings, DiaSource, Abbott, Agilent Technologies, Inc., Lee Biosolutions, Inc, MP BIOMEDICALS, Setia Scientific Solution, Boditech Med Inc., AccuBioTech Co., Ltd., Thermo Fisher Scientific, Creative Biolabs, Myriad Genetics, Inc., BD, CANON MEDICAL SYSTEMS CORPORATION, QIAGEN, Meridian Life Science, Inc., CTK Biotech, Inc., entre autres.
SKU-
Accédez en ligne au rapport sur le premier cloud mondial de veille économique
- Tableau de bord d'analyse de données interactif
- Tableau de bord d'analyse d'entreprise pour les opportunités à fort potentiel de croissance
- Accès d'analyste de recherche pour la personnalisation et les requêtes
- Analyse de la concurrence avec tableau de bord interactif
- Dernières actualités, mises à jour et analyse des tendances
- Exploitez la puissance de l'analyse comparative pour un suivi complet de la concurrence
Table des matières
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF THE EUROPE PANCREATIC CANCER DIAGNOSTICS MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATIONS
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 DBMR TRIPOD DATA VALIDATION MODEL
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.6 MULTIVARIATE MODELLING
2.7 MARKET END USER COVERAGE GRID
2.8 PRODUCT LIFELINE CURVE
2.9 DBMR MARKET POSITION GRID
2.1 VENDOR SHARE ANALYSIS
2.11 SECONDARY SOURCES
2.12 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTEL ANALYSIS
4.2 PORTER’S FIVE FORCES MODEL
5 EUROPE PANCREATIC CANCER DIAGNOSTICS MARKET, INDUSTRY INSIGHTS
6 EPIDEMIOLOGY
7 EUROPE PANCREATIC CANCER DIAGNOSTICS MARKET, REGULATIONS
8 MARKET OVERVIEW
8.1 DRIVERS
8.1.1 GROW IN PREVALENCE OF PANCREATIC CANCER
8.1.2 NOVEL TECHNOLOGICAL ADVANCEMENTS IN PANCREATIC DIAGNOSTICS
8.1.3 RISING PREFERENCE FOR PREVENTIVE HEALTH CHECK-UPS
8.1.4 INCREASE IN AWARENESS REGARDING PANCREATIC CANCER
8.2 RESTRAINTS
8.2.1 STRICT REGULATIONS AND STANDARDS FOR THE APPROVAL AND COMMERCIALIZATION OF PANCREATIC CANCER DIAGNOSTIC PRODUCTS
8.2.2 LATE DIAGNOSIS AND POOR PROGNOSIS OF PANCREATIC CANCER
8.3 OPPORTUNITIES
8.3.1 INCREASE IN DIAGNOSTIC PRODUCTS FOR PANCREATIC CANCER
8.3.2 RISE IN HEALTHCARE EXPENDITURE FOR CANCER DIAGNOSIS AND TREATMENT
8.3.3 GOVERNMENT INITIATIVES TOWARD PANCREATIC CANCER DIAGNOSTICS
8.4 CHALLENGES
8.4.1 INCREASED COST, SAFETY, AND CONVENIENCE ISSUES
8.4.2 LACK OF SKILLED AND CERTIFIED PROFESSIONALS
9 EUROPE PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE
9.1 OVERVIEW
9.2 IMAGING TEST
9.2.1 COMPUTED TOMOGRAPHY (CT) SCAN
9.2.2 MAGNETIC RESONANCE IMAGING (MRI)
9.2.2.1 MR CHOLANGIOPANCREATOGRAPHY
9.2.2.2 MR ANGIOGRAPHY (MRA)
9.2.3 ULTRASOUND
9.2.3.1 ABDOMINAL ULTRASOUND
9.2.3.2 ENDOSCOPIC ULTRASOUND (EUS)
9.2.4 CHOLANGIOPANCREATOGRAPHY
9.2.4.1 MAGNETIC RESONANCE CHOLANGIOPANCREATOGRAPHY (MRCP)
9.2.4.2 ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY (ERCP)
9.2.4.3 PRECUTANEOUS TRANSHEPTIC CHOLANGIOPANCREATOGRAPHY (PTC)
9.2.5 POSITRON EMISSION TOMOHRAPHY (PET)
9.2.6 OTHERS
9.3 BIOPSY
9.3.1 CT-GUIDED NEEDLE BIOPSY
9.3.2 FINE NEEDLE ASPIRATION (FNA)
9.3.3 CORE NEEDLE BIOPSY
9.3.4 OTHERS
9.4 BLOOD TEST
9.4.1 LIVER FUNCTION TEST
9.4.2 TUMOR MARKER
9.4.2.1 CA 19-9 BIOMARKER TEST
9.4.2.2 CARCINOEMBROYNIC ANTIGEN (CEA) TEST
9.4.2.3 CA 50 MARKER TEST
9.4.2.4 OTHERS
9.4.3 OTHERS
9.5 GENOMIC TEST
9.6 OTHERS
10 EUROPE PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGES
10.1 OVERVIEW
10.2 STAGE IV
10.3 STAGE III
10.4 STAGE II
10.4.1 STAGE IIA
10.4.2 STAGE IIB
10.5 STAGE I
10.5.1 STAGE IA
10.5.2 STAGE IB
10.6 STAGE 0
11 EUROPE PANCREATIC CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE
11.1 OVERVIEW
11.2 EXOCRINE TUMORS
11.2.1 INSTRUMENT-BASED PRODUCTS
11.2.2 PLATFORM-BASED PRODUCTS
11.2.3 KITS AND REAGENTS
11.2.4 OTHER CONSUMABLES
11.3 NEUROENDOCRINE TUMORS
11.3.1 INSTRUMENT-BASED PRODUCTS
11.3.2 PLATFORM-BASED PRODUCTS
11.3.3 KITS AND REAGENTS
11.3.4 OTHER CONSUMABLES
12 EUROPE PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT
12.1 OVERVIEW
12.2 INSTRUMENT-BASED PRODUCTS
12.2.1 IMAGING
12.2.2 BIOPSY
12.3 PLATFORM-BASED PRODUCTS
12.3.1 NEXT-GENERATION SEQUENCING
12.3.2 MICROARRAYS
12.3.3 PCR
12.3.4 OTHERS
12.4 KITS AND REAGENTS
12.4.1 CA19-9 PANCREATIC CANCER TEST KITS
12.4.1.1 ELISA TEST KITS
12.4.1.2 CASETTE TEST KITS
12.4.1.3 OTHERS
12.4.2 CEA PANCREATIC CANCER TEST KITS
12.4.2.1 ELISA TEST KITS
12.4.2.2 CASETTE TEST KITS
12.4.2.3 OTHERS
12.5 OTHER CONSUMABLES
13 EUROPE PANCREATIC CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY
13.1 OVERVIEW
13.2 FLUORESCENT IN SITU HYBRIDIZATION
13.3 NEXT GENERATION SEQUENCING
13.4 FLUORIMMUNOASSAY
13.5 COMPARATIVE GENOMIC HYBRIDIZATION
13.6 IMMUNOHISTOCHEMICAL
13.7 OTHERS
14 EUROPE PANCREATIC CANCER DIAGNOSTICS MARKET, BY APPLICATION
14.1 OVERVIEW
14.2 SCREENING
14.2.1 INSTRUMENT-BASED PRODUCTS
14.2.2 PLATFORM-BASED PRODUCTS
14.2.3 KITS AND REAGENTS
14.2.4 OTHER CONSUMABLES
14.3 DIAGNOSTIC AND PREDICTIVE
14.3.1 INSTRUMENT-BASED PRODUCTS
14.3.2 PLATFORM-BASED PRODUCTS
14.3.3 KITS AND REAGENTS
14.3.4 OTHER CONSUMABLES
14.4 PROGNOSTIC
14.4.1 INSTRUMENT-BASED PRODUCTS
14.4.2 PLATFORM-BASED PRODUCTS
14.4.3 KITS AND REAGENTS
14.4.4 OTHER CONSUMABLES
14.5 RESEARCH
14.5.1 INSTRUMENT-BASED PRODUCTS
14.5.2 PLATFORM-BASED PRODUCTS
14.5.3 KITS AND REAGENTS
14.5.4 OTHER CONSUMABLES
15 EUROPE PANCREATIC CANCER DIAGNOSTICS MARKET, BY END USER
15.1 OVERVIEW
15.2 HOSPITALS
15.3 DIAGNOSTIC CENTERS
15.4 CANCER RESEARCH CENTERS
15.5 ACADEMIC INSTITUTES
15.6 AMBULATORY SURGICAL CENTERS
15.7 OTHERS
16 EUROPE PANCREATIC CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL
16.1 OVERVIEW
16.2 DIRECT TENDER
16.3 RETAIL SALES
16.4 OTHERS
17 EUROPE PANCREATIC CANCER DIAGNOSTICS MARKET, BY REGION
17.1 EUROPE
17.1.1 GERMANY
17.1.2 FRANCE
17.1.3 UNITED KINGDOM
17.1.4 ITALY
17.1.5 SPAIN
17.1.6 RUSSIA
17.1.7 NETHERLANDS
17.1.8 POLAND
17.1.9 SWITZERLAND
17.1.10 BELGIUM
17.1.11 SWEDEN
17.1.12 NORWAY
17.1.13 DENMARK
17.1.14 FINLAND
17.1.15 TURKEY
17.1.16 REST OF EUROPE
18 EUROPE PANCREATIC CANCER DIAGNOSTICS MARKET: COMPANY LANDSCAPE
18.1 COMPANY SHARE ANALYSIS: EUROPE
19 SWOT ANALYSIS
20 EUROPE PANCREATIC CANCER DIAGNOSTICS MARKET
20.1 CANON MEDICAL SYSTEMS CORPORATION
20.1.1 COMPANY SNAPSHOT
20.1.2 REVENUE ANALYSIS
20.1.3 COMPANY SHARE ANALYSIS
20.1.4 PRODUCT PORTFOLIO
20.1.5 RECENT DEVELOPMENT
20.2 KONINKLIJKE PHILIPS N.V.
20.2.1 COMPANY SNAPSHOT
20.2.2 REVENUE ANALYSIS
20.2.3 COMPANY SHARE ANALYSIS
20.2.4 PRODUCT PORTFOLIO
20.2.5 RECENT DEVELOPMENTS
20.3 SIEMENS HEALTHCARE GMBH
20.3.1 COMPANY SNAPSHOT
20.3.2 REVENUE ANALYSIS
20.3.3 COMPANY SHARE ANALYSIS
20.3.4 PRODUCT PORTFOLIO
20.3.5 RECENT DEVELOPMENT
20.4 GRAIL
20.4.1 COMPANY PROFILE
20.4.2 COMPANY SHARE ANALYSIS
20.4.3 PRODUCT PORTFOLIO
20.4.4 RECENT DEVELOPMENT
20.5 MYRIAD GENETICS, INC.
20.5.1 COMPANY SNAPSHOT
20.5.2 REVENUE ANALYSIS
20.5.3 COMPANY SHARE ANALYSIS
20.5.4 PRODUCT PORTFOLIO
20.5.5 RECENT DEVELOPMENT
20.6 BD
20.6.1 COMPANY SNAPSHOT
20.6.2 REVENUE ANALYSIS
20.6.3 PRODUCT PORTFOLIO
20.6.4 RECENT DEVELOPMENT
20.7 BODITECH MED INC.
20.7.1 COMPANY PROFILE
20.7.2 PRODUCT PORTFOLIO
20.7.3 RECENT DEVELOPMENT
20.8 ABBOTT (2022)
20.8.1 COMPANY SNAPSHOT
20.8.2 REVENUE ANALYSIS
20.8.3 PRODUCT PORTFOLIO
20.8.4 RECENT DEVELOPMENT
20.9 FUJIFILM HOLDINGS AMERICA CORPORATION
20.9.1 COMPANY SNAPSHOT
20.9.2 REVENUE ANALYSIS
20.9.3 PRODUCT PORTFOLIO
20.9.4 RECENT DEVELOPMENT
20.1 ACCUBIOTECH CO., LTD.
20.10.1 COMPANY PROFILE
20.10.2 PRODUCT PORTFOLIO
20.10.3 RECENT DEVELOPMENTS
20.11 AGILENT TECHNOLOGIES, INC.
20.11.1 COMPANY PROFILE
20.11.2 REVENUE ANALYSIS
20.11.3 PRODUCT PORTFOLIO
20.11.4 RECENT DEVELOPMENT
20.12 CREATIVE BIOLABS.
20.12.1 COMPANY PROFILE
20.12.2 PRODUCT PORTFOLIO
20.12.3 RECENT DEVELOPMENT
20.13 CTK BIOTECH, INC.
20.13.1 COMPANY PROFILE
20.13.2 PRODUCT PORTFOLIO
20.13.3 RECENT DEVELOPMENT
20.14 DIASOURCE
20.14.1 COMPANY SNAPSHOT
20.14.2 PRODUCT PORTFOLIO
20.14.3 RECENT DEVELOPMENT
20.15 LABORATORY CORPORATION OF AMERICA HOLDINGS
20.15.1 COMPANY SNAPSHOT
20.15.2 REVENUE ANALYSIS
20.15.3 PRODUCT PORTFOLIO
20.15.4 RECENT DEVELOPMENTS
20.16 LEE BIOSCIENCE
20.16.1 COMPANY SNAPSHOT
20.16.2 PRODUCT PORTFOLIO
20.16.3 RECENT DEVELOPMENT
20.17 MERIDIAN BIOSCIENCE INC.
20.17.1 COMPANY PROFILE
20.17.2 PRODUCT PORTFOLIO
20.17.3 RECENT DEVELOPMENT
20.18 MP BIOMEDICALS.
20.18.1 COMPANY PROFILE
20.18.2 PRODUCT PORTFOLIO
20.18.3 RECENT DEVELOPMENTS
20.19 QIAGEN
20.19.1 COMPANY SNAPSHOT
20.19.2 REVENUE ANALYSIS
20.19.3 PRODUCT PORTFOLIO
20.19.4 RECENT DEVELOPMENT
20.2 SETIA SCIENTIFIC SOLUTION
20.20.1 COMPANY PROFILE
20.20.2 PRODUCT PORTFOLIO
20.20.3 RECENT DEVELOPMENTS
20.21 THERMO FISHER SCIENTIFIC INC.
20.21.1 COMPANY SNAPSHOT
20.21.2 REVENUE ANALYSIS
20.21.3 PRODUCT PORTFOLIO
20.21.4 RECENT DEVELOPMENT
21 QUESTIONNAIRE
22 RELATED REPORTS
Liste des tableaux
TABLE 1 APPROVED DIAGNOSTICS OF PANCREATIC CANCER
TABLE 2 EUROPE PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 3 EUROPE IMAGING TEST IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 4 EUROPE IMAGING TEST IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 5 EUROPE MAGNETIC RESONANCE IMAGING (MRI) IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 6 EUROPE ULTRASOUND IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 7 EUROPE CHOLANGIOPANCREATOGRAPHY IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 8 EUROPE BIOPSY IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 9 EUROPE BIOPSY IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 10 EUROPE BLOOD TEST IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 11 EUROPE BLOOD TEST IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 12 EUROPE TUMOR MARKER IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 13 EUROPE GENOMIC TEST IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 14 EUROPE OTHERS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 15 EUROPE PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGES, 2021-2030 (USD MILLION)
TABLE 16 EUROPE STAGE IV IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 17 EUROPE STAGE III IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 18 EUROPE STAGE II IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 19 EUROPE STAGE II IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)
TABLE 20 EUROPE STAGE I IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 21 EUROPE STAGE I IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)
TABLE 22 EUROPE STAGE 0 IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 23 EUROPE PANCREATIC CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)
TABLE 24 EUROPE EXOCRINE TUMORS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 25 EUROPE EXOCRINE TUMORS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 26 EUROPE NEUROENDOCRINE TUMORS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 27 EUROPE NEUROENDOCRINE TUMORS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 28 EUROPE PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 29 EUROPE INSTRUMENT-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 30 EUROPE INSTRUMENT-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 31 EUROPE PLATFORM-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 32 EUROPE PLATFORM-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 33 EUROPE KITS AND REAGENTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 34 EUROPE KITS AND REAGENTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 35 EUROPE CA19-9 PANCREATIC CANCER TEST KITS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 36 EUROPE CEA PANCREATIC CANCER TEST KITS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 37 EUROPE OTHER CONSUMABLES IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 38 EUROPE PANCREATIC CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 39 EUROPE FLUORESCENT IN SITU HYBRIDIZATION IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 40 EUROPE NEXT GENERATION SEQUENCING IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 41 EUROPE FLUORIMMUNOASSAY IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 42 EUROPE COMPARATIVE GENOMIC HYBRIDIZATION IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 43 EUROPE IMMUNOHISTOCHEMICAL IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 44 EUROPE OTHERS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 45 EUROPE PANCREATIC CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 46 EUROPE SCREENING IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 47 EUROPE SCREENING IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 48 EUROPE DIAGNOSTIC AND PREDICTIVE IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 49 EUROPE DIAGNOSTIC AND PREDICTIVE IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 50 EUROPE PROGNOSTIC IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 51 EUROPE PROGNOSTIC IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 52 EUROPE RESEARCH IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 53 EUROPE RESEARCH IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 54 EUROPE PANCREATIC CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 55 EUROPE HOSPITALS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 56 EUROPE DIAGNOSTIC CENTERS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 57 EUROPE CANCER RESEARCH CENTERS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 58 EUROPE ACADEMIC INSTITUTES IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 59 EUROPE AMBULATORY SURGICAL CENTERS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 60 EUROPE OTHERS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 61 EUROPE PANCREATIC CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 62 EUROPE DIRECT TENDER IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 63 EUROPE RETAIL SALES IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 64 EUROPE OTHERS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 65 EUROPE PANCREATIC CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2021-2030 (USD MILLION)
TABLE 66 EUROPE PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 67 EUROPE IMAGING TEST IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 68 EUROPE MAGNETIC RESONANCE IMAGING (MRI) IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 69 EUROPE ULTRASOUND IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 70 EUROPE CHOLANGIOPANCREATOGRAPHY IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 71 EUROPE BLOOD TEST IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 72 EUROPE TUMOR MARKER IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 73 EUROPE BIOPSY IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 74 EUROPE PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)
TABLE 75 EUROPE STAGE I IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)
TABLE 76 EUROPE STAGE II IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)
TABLE 77 EUROPE PANCREATIC CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)
TABLE 78 EUROPE EXOCRINE TUMORS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 79 EUROPE NEUROENDOCRINE TUMORS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 80 EUROPE PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 81 EUROPE INSTRUMENT-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 82 EUROPE INSTRUMENT-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 83 EUROPE INSTRUMENT-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)
TABLE 84 EUROPE PLATFORM-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 85 EUROPE PLATFORM-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 86 EUROPE PLATFORM-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)
TABLE 87 EUROPE KITS AND REAGENTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 88 EUROPE CA19-9 PANCREATIC CANCER TEST KITS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 89 EUROPE CEA PANCREATIC CANCER TEST KITS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 90 EUROPE PANCREATIC CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 91 EUROPE PANCREATIC CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 92 EUROPE SCREENING IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 93 EUROPE DIAGNOSTIC AND PREDICTIVE IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 94 EUROPE PROGNOSTIC IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 95 EUROPE RESEARCH IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 96 EUROPE PANCREATIC CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 97 EUROPE PANCREATIC CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 98 GERMANY PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 99 GERMANY IMAGING TEST IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 100 GERMANY MAGNETIC RESONANCE IMAGING (MRI) IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 101 GERMANY ULTRASOUND IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 102 GERMANY CHOLANGIOPANCREATOGRAPHY IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 103 GERMANY BLOOD TEST IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 104 GERMANY TUMOR MARKER IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 105 GERMANY BIOPSY IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 106 GERMANY PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)
TABLE 107 GERMANY STAGE I IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)
TABLE 108 GERMANY STAGE II IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)
TABLE 109 GERMANY PANCREATIC CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)
TABLE 110 GERMANY EXOCRINE TUMORS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 111 GERMANY NEUROENDOCRINE TUMORS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 112 GERMANY PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 113 GERMANY INSTRUMENT-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 114 GERMANY INSTRUMENT-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 115 GERMANY INSTRUMENT-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)
TABLE 116 GERMANY PLATFORM-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 117 GERMANY PLATFORM-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 118 GERMANY PLATFORM-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)
TABLE 119 GERMANY KITS AND REAGENTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 120 GERMANY CA19-9 PANCREATIC CANCER TEST KITS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 121 GERMANY CEA PANCREATIC CANCER TEST KITS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 122 GERMANY PANCREATIC CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 123 GERMANY PANCREATIC CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 124 GERMANY SCREENING IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 125 GERMANY DIAGNOSTIC AND PREDICTIVE IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 126 GERMANY PROGNOSTIC IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 127 GERMANY RESEARCH IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 128 GERMANY PANCREATIC CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 129 GERMANY PANCREATIC CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 130 FRANCE PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 131 FRANCE IMAGING TEST IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 132 FRANCE MAGNETIC RESONANCE IMAGING (MRI) IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 133 FRANCE ULTRASOUND IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 134 FRANCE CHOLANGIOPANCREATOGRAPHY IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 135 FRANCE BLOOD TEST IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 136 FRANCE TUMOR MARKER IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 137 FRANCE BIOPSY IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 138 FRANCE PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)
TABLE 139 FRANCE STAGE I IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)
TABLE 140 FRANCE STAGE II IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)
TABLE 141 FRANCE PANCREATIC CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)
TABLE 142 FRANCE EXOCRINE TUMORS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 143 FRANCE NEUROENDOCRINE TUMORS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 144 FRANCE PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 145 FRANCE INSTRUMENT-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 146 FRANCE INSTRUMENT-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 147 FRANCE INSTRUMENT-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)
TABLE 148 FRANCE PLATFORM-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 149 FRANCE PLATFORM-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 150 FRANCE PLATFORM-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)
TABLE 151 FRANCE KITS AND REAGENTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 152 FRANCE CA19-9 PANCREATIC CANCER TEST KITS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 153 FRANCE CEA PANCREATIC CANCER TEST KITS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 154 FRANCE PANCREATIC CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 155 FRANCE PANCREATIC CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 156 FRANCE SCREENING IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 157 FRANCE DIAGNOSTIC AND PREDICTIVE IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 158 FRANCE PROGNOSTIC IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 159 FRANCE RESEARCH IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 160 FRANCE PANCREATIC CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 161 FRANCE PANCREATIC CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 162 UNITED KINGDOM PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 163 UNITED KINGDOM IMAGING TEST IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 164 UNITED KINGDOM MAGNETIC RESONANCE IMAGING (MRI) IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 165 UNITED KINGDOM ULTRASOUND IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 166 UNITED KINGDOM CHOLANGIOPANCREATOGRAPHY IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 167 UNITED KINGDOM BLOOD TEST IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 168 UNITED KINGDOM TUMOR MARKER IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 169 UNITED KINGDOM BIOPSY IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 170 UNITED KINGDOM PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)
TABLE 171 UNITED KINGDOM STAGE I IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)
TABLE 172 UNITED KINGDOM STAGE II IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)
TABLE 173 UNITED KINGDOM PANCREATIC CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)
TABLE 174 UNITED KINGDOM EXOCRINE TUMORS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 175 UNITED KINGDOM NEUROENDOCRINE TUMORS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 176 UNITED KINGDOM PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 177 UNITED KINGDOM INSTRUMENT-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 178 UNITED KINGDOM INSTRUMENT-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 179 UNITED KINGDOM INSTRUMENT-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)
TABLE 180 UNITED KINGDOM PLATFORM-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 181 UNITED KINGDOM PLATFORM-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 182 UNITED KINGDOM PLATFORM-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)
TABLE 183 UNITED KINGDOM KITS AND REAGENTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 184 UNITED KINGDOM CA19-9 PANCREATIC CANCER TEST KITS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 185 UNITED KINGDOM CEA PANCREATIC CANCER TEST KITS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 186 UNITED KINGDOM PANCREATIC CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 187 UNITED KINGDOM PANCREATIC CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 188 UNITED KINGDOM SCREENING IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 189 UNITED KINGDOM DIAGNOSTIC AND PREDICTIVE IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 190 UNITED KINGDOM PROGNOSTIC IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 191 UNITED KINGDOM RESEARCH IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 192 UNITED KINGDOM PANCREATIC CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 193 UNITED KINGDOM PANCREATIC CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 194 ITALY PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 195 ITALY IMAGING TEST IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 196 ITALY MAGNETIC RESONANCE IMAGING (MRI) IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 197 ITALY ULTRASOUND IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 198 ITALY CHOLANGIOPANCREATOGRAPHY IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 199 ITALY BLOOD TEST IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 200 ITALY TUMOR MARKER IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 201 ITALY BIOPSY IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 202 ITALY PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)
TABLE 203 ITALY STAGE I IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)
TABLE 204 ITALY STAGE II IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)
TABLE 205 ITALY PANCREATIC CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)
TABLE 206 ITALY EXOCRINE TUMORS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 207 ITALY NEUROENDOCRINE TUMORS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 208 ITALY PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 209 ITALY INSTRUMENT-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 210 ITALY INSTRUMENT-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 211 ITALY INSTRUMENT-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)
TABLE 212 ITALY PLATFORM-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 213 ITALY PLATFORM-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 214 ITALY PLATFORM-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)
TABLE 215 ITALY KITS AND REAGENTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 216 ITALY CA19-9 PANCREATIC CANCER TEST KITS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 217 ITALY CEA PANCREATIC CANCER TEST KITS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 218 ITALY PANCREATIC CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 219 ITALY PANCREATIC CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 220 ITALY SCREENING IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 221 ITALY DIAGNOSTIC AND PREDICTIVE IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 222 ITALY PROGNOSTIC IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 223 ITALY RESEARCH IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 224 ITALY PANCREATIC CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 225 ITALY PANCREATIC CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 226 SPAIN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 227 SPAIN IMAGING TEST IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 228 SPAIN MAGNETIC RESONANCE IMAGING (MRI) IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 229 SPAIN ULTRASOUND IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 230 SPAIN CHOLANGIOPANCREATOGRAPHY IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 231 SPAIN BLOOD TEST IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 232 SPAIN TUMOR MARKER IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 233 SPAIN BIOPSY IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 234 SPAIN PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)
TABLE 235 SPAIN STAGE I IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)
TABLE 236 SPAIN STAGE II IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)
TABLE 237 SPAIN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)
TABLE 238 SPAIN EXOCRINE TUMORS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 239 SPAIN NEUROENDOCRINE TUMORS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 240 SPAIN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 241 SPAIN INSTRUMENT-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 242 SPAIN INSTRUMENT-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 243 SPAIN INSTRUMENT-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)
TABLE 244 SPAIN PLATFORM-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 245 SPAIN PLATFORM-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 246 SPAIN PLATFORM-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)
TABLE 247 SPAIN KITS AND REAGENTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 248 SPAIN CA19-9 PANCREATIC CANCER TEST KITS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 249 SPAIN CEA PANCREATIC CANCER TEST KITS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 250 SPAIN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 251 SPAIN PANCREATIC CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 252 SPAIN SCREENING IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 253 SPAIN DIAGNOSTIC AND PREDICTIVE IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 254 SPAIN PROGNOSTIC IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 255 SPAIN RESEARCH IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 256 SPAIN PANCREATIC CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 257 SPAIN PANCREATIC CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 258 RUSSIA PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 259 RUSSIA IMAGING TEST IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 260 RUSSIA MAGNETIC RESONANCE IMAGING (MRI) IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 261 RUSSIA ULTRASOUND IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 262 RUSSIA CHOLANGIOPANCREATOGRAPHY IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 263 RUSSIA BLOOD TEST IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 264 RUSSIA TUMOR MARKER IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 265 RUSSIA BIOPSY IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 266 RUSSIA PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)
TABLE 267 RUSSIA STAGE I IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)
TABLE 268 RUSSIA STAGE II IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)
TABLE 269 RUSSIA PANCREATIC CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)
TABLE 270 RUSSIA EXOCRINE TUMORS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 271 RUSSIA NEUROENDOCRINE TUMORS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 272 RUSSIA PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 273 RUSSIA INSTRUMENT-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 274 RUSSIA INSTRUMENT-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 275 RUSSIA INSTRUMENT-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)
TABLE 276 RUSSIA PLATFORM-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 277 RUSSIA PLATFORM-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 278 RUSSIA PLATFORM-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)
TABLE 279 RUSSIA KITS AND REAGENTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 280 RUSSIA CA19-9 PANCREATIC CANCER TEST KITS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 281 RUSSIA CEA PANCREATIC CANCER TEST KITS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 282 RUSSIA PANCREATIC CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 283 RUSSIA PANCREATIC CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 284 RUSSIA SCREENING IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 285 RUSSIA DIAGNOSTIC AND PREDICTIVE IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 286 RUSSIA PROGNOSTIC IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 287 RUSSIA RESEARCH IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 288 RUSSIA PANCREATIC CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 289 RUSSIA PANCREATIC CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 290 NETHERLANDS PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 291 NETHERLANDS IMAGING TEST IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 292 NETHERLANDS MAGNETIC RESONANCE IMAGING (MRI) IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 293 NETHERLANDS ULTRASOUND IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 294 NETHERLANDS CHOLANGIOPANCREATOGRAPHY IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 295 NETHERLANDS BLOOD TEST IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 296 NETHERLANDS TUMOR MARKER IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 297 NETHERLANDS BIOPSY IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 298 NETHERLANDS PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)
TABLE 299 NETHERLANDS STAGE I IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)
TABLE 300 NETHERLANDS STAGE II IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)
TABLE 301 NETHERLANDS PANCREATIC CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)
TABLE 302 NETHERLANDS EXOCRINE TUMORS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 303 NETHERLANDS NEUROENDOCRINE TUMORS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 304 NETHERLANDS PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 305 NETHERLANDS INSTRUMENT-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 306 NETHERLANDS INSTRUMENT-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 307 NETHERLANDS INSTRUMENT-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)
TABLE 308 NETHERLANDS PLATFORM-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 309 NETHERLANDS PLATFORM-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 310 NETHERLANDS PLATFORM-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)
TABLE 311 NETHERLANDS KITS AND REAGENTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 312 NETHERLANDS CA19-9 PANCREATIC CANCER TEST KITS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 313 NETHERLANDS CEA PANCREATIC CANCER TEST KITS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 314 NETHERLANDS PANCREATIC CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 315 NETHERLANDS PANCREATIC CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 316 NETHERLANDS SCREENING IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 317 NETHERLANDS DIAGNOSTIC AND PREDICTIVE IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 318 NETHERLANDS PROGNOSTIC IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 319 NETHERLANDS RESEARCH IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 320 NETHERLANDS PANCREATIC CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 321 NETHERLANDS PANCREATIC CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 322 POLAND PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 323 POLAND IMAGING TEST IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 324 POLAND MAGNETIC RESONANCE IMAGING (MRI) IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 325 POLAND ULTRASOUND IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 326 POLAND CHOLANGIOPANCREATOGRAPHY IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 327 POLAND BLOOD TEST IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 328 POLAND TUMOR MARKER IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 329 POLAND BIOPSY IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 330 POLAND PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)
TABLE 331 POLAND STAGE I IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)
TABLE 332 POLAND STAGE II IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)
TABLE 333 POLAND PANCREATIC CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)
TABLE 334 POLAND EXOCRINE TUMORS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 335 POLAND NEUROENDOCRINE TUMORS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 336 POLAND PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 337 POLAND INSTRUMENT-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 338 POLAND INSTRUMENT-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 339 POLAND INSTRUMENT-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)
TABLE 340 POLAND PLATFORM-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 341 POLAND PLATFORM-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 342 POLAND PLATFORM-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)
TABLE 343 POLAND KITS AND REAGENTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 344 POLAND CA19-9 PANCREATIC CANCER TEST KITS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 345 POLAND CEA PANCREATIC CANCER TEST KITS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 346 POLAND PANCREATIC CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 347 POLAND PANCREATIC CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 348 POLAND SCREENING IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 349 POLAND DIAGNOSTIC AND PREDICTIVE IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 350 POLAND PROGNOSTIC IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 351 POLAND RESEARCH IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 352 POLAND PANCREATIC CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 353 POLAND PANCREATIC CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 354 SWITZERLAND PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 355 SWITZERLAND IMAGING TEST IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 356 SWITZERLAND MAGNETIC RESONANCE IMAGING (MRI) IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 357 SWITZERLAND ULTRASOUND IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 358 SWITZERLAND CHOLANGIOPANCREATOGRAPHY IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 359 SWITZERLAND BLOOD TEST IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 360 SWITZERLAND TUMOR MARKER IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 361 SWITZERLAND BIOPSY IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 362 SWITZERLAND PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)
TABLE 363 SWITZERLAND STAGE I IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)
TABLE 364 SWITZERLAND STAGE II IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)
TABLE 365 SWITZERLAND PANCREATIC CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)
TABLE 366 SWITZERLAND EXOCRINE TUMORS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 367 SWITZERLAND NEUROENDOCRINE TUMORS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 368 SWITZERLAND PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 369 SWITZERLAND INSTRUMENT-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 370 SWITZERLAND INSTRUMENT-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 371 SWITZERLAND INSTRUMENT-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)
TABLE 372 SWITZERLAND PLATFORM-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 373 SWITZERLAND PLATFORM-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 374 SWITZERLAND PLATFORM-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)
TABLE 375 SWITZERLAND KITS AND REAGENTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 376 SWITZERLAND CA19-9 PANCREATIC CANCER TEST KITS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 377 SWITZERLAND CEA PANCREATIC CANCER TEST KITS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 378 SWITZERLAND PANCREATIC CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 379 SWITZERLAND PANCREATIC CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 380 SWITZERLAND SCREENING IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 381 SWITZERLAND DIAGNOSTIC AND PREDICTIVE IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 382 SWITZERLAND PROGNOSTIC IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 383 SWITZERLAND RESEARCH IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 384 SWITZERLAND PANCREATIC CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 385 SWITZERLAND PANCREATIC CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 386 BELGIUM PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 387 BELGIUM IMAGING TEST IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 388 BELGIUM MAGNETIC RESONANCE IMAGING (MRI) IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 389 BELGIUM ULTRASOUND IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 390 BELGIUM CHOLANGIOPANCREATOGRAPHY IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 391 BELGIUM BLOOD TEST IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 392 BELGIUM TUMOR MARKER IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 393 BELGIUM BIOPSY IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 394 BELGIUM PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)
TABLE 395 BELGIUM STAGE I IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)
TABLE 396 BELGIUM STAGE II IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)
TABLE 397 BELGIUM PANCREATIC CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)
TABLE 398 BELGIUM EXOCRINE TUMORS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 399 BELGIUM NEUROENDOCRINE TUMORS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 400 BELGIUM PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 401 BELGIUM INSTRUMENT-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 402 BELGIUM INSTRUMENT-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 403 BELGIUM INSTRUMENT-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)
TABLE 404 BELGIUM PLATFORM-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 405 BELGIUM PLATFORM-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 406 BELGIUM PLATFORM-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)
TABLE 407 BELGIUM KITS AND REAGENTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 408 BELGIUM CA19-9 PANCREATIC CANCER TEST KITS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 409 BELGIUM CEA PANCREATIC CANCER TEST KITS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 410 BELGIUM PANCREATIC CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 411 BELGIUM PANCREATIC CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 412 BELGIUM SCREENING IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 413 BELGIUM DIAGNOSTIC AND PREDICTIVE IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 414 BELGIUM PROGNOSTIC IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 415 BELGIUM RESEARCH IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 416 BELGIUM PANCREATIC CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 417 BELGIUM PANCREATIC CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 418 SWEDEN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 419 SWEDEN IMAGING TEST IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 420 SWEDEN MAGNETIC RESONANCE IMAGING (MRI) IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 421 SWEDEN ULTRASOUND IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 422 SWEDEN CHOLANGIOPANCREATOGRAPHY IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 423 SWEDEN BLOOD TEST IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 424 SWEDEN TUMOR MARKER IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 425 SWEDEN BIOPSY IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 426 SWEDEN PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)
TABLE 427 SWEDEN STAGE I IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)
TABLE 428 SWEDEN STAGE II IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)
TABLE 429 SWEDEN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)
TABLE 430 SWEDEN EXOCRINE TUMORS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 431 SWEDEN NEUROENDOCRINE TUMORS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 432 SWEDEN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 433 SWEDEN INSTRUMENT-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 434 SWEDEN INSTRUMENT-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 435 SWEDEN INSTRUMENT-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)
TABLE 436 SWEDEN PLATFORM-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 437 SWEDEN PLATFORM-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 438 SWEDEN PLATFORM-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)
TABLE 439 SWEDEN KITS AND REAGENTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 440 SWEDEN CA19-9 PANCREATIC CANCER TEST KITS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 441 SWEDEN CEA PANCREATIC CANCER TEST KITS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 442 SWEDEN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 443 SWEDEN PANCREATIC CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 444 SWEDEN SCREENING IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 445 SWEDEN DIAGNOSTIC AND PREDICTIVE IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 446 SWEDEN PROGNOSTIC IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 447 SWEDEN RESEARCH IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 448 SWEDEN PANCREATIC CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 449 SWEDEN PANCREATIC CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 450 NORWAY PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 451 NORWAY IMAGING TEST IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 452 NORWAY MAGNETIC RESONANCE IMAGING (MRI) IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 453 NORWAY ULTRASOUND IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 454 NORWAY CHOLANGIOPANCREATOGRAPHY IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 455 NORWAY BLOOD TEST IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 456 NORWAY TUMOR MARKER IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 457 NORWAY BIOPSY IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 458 NORWAY PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)
TABLE 459 NORWAY STAGE I IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)
TABLE 460 NORWAY STAGE II IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)
TABLE 461 NORWAY PANCREATIC CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)
TABLE 462 NORWAY EXOCRINE TUMORS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 463 NORWAY NEUROENDOCRINE TUMORS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 464 NORWAY PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 465 NORWAY INSTRUMENT-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 466 NORWAY INSTRUMENT-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 467 NORWAY INSTRUMENT-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)
TABLE 468 NORWAY PLATFORM-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 469 NORWAY PLATFORM-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 470 NORWAY PLATFORM-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)
TABLE 471 NORWAY KITS AND REAGENTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 472 NORWAY CA19-9 PANCREATIC CANCER TEST KITS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 473 NORWAY CEA PANCREATIC CANCER TEST KITS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 474 NORWAY PANCREATIC CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 475 NORWAY PANCREATIC CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 476 NORWAY SCREENING IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 477 NORWAY DIAGNOSTIC AND PREDICTIVE IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 478 NORWAY PROGNOSTIC IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 479 NORWAY RESEARCH IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 480 NORWAY PANCREATIC CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 481 NORWAY PANCREATIC CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 482 DENMARK PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 483 DENMARK IMAGING TEST IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 484 DENMARK MAGNETIC RESONANCE IMAGING (MRI) IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 485 DENMARK ULTRASOUND IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 486 DENMARK CHOLANGIOPANCREATOGRAPHY IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 487 DENMARK BLOOD TEST IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 488 DENMARK TUMOR MARKER IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 489 DENMARK BIOPSY IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 490 DENMARK PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)
TABLE 491 DENMARK STAGE I IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)
TABLE 492 DENMARK STAGE II IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)
TABLE 493 DENMARK PANCREATIC CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)
TABLE 494 DENMARK EXOCRINE TUMORS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 495 DENMARK NEUROENDOCRINE TUMORS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 496 DENMARK PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 497 DENMARK INSTRUMENT-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 498 DENMARK INSTRUMENT-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 499 DENMARK INSTRUMENT-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)
TABLE 500 DENMARK PLATFORM-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 501 DENMARK PLATFORM-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 502 DENMARK PLATFORM-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)
TABLE 503 DENMARK KITS AND REAGENTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 504 DENMARK CA19-9 PANCREATIC CANCER TEST KITS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 505 DENMARK CEA PANCREATIC CANCER TEST KITS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 506 DENMARK PANCREATIC CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 507 DENMARK PANCREATIC CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 508 DENMARK SCREENING IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 509 DENMARK DIAGNOSTIC AND PREDICTIVE IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 510 DENMARK PROGNOSTIC IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 511 DENMARK RESEARCH IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 512 DENMARK PANCREATIC CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 513 DENMARK PANCREATIC CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 514 FINLAND IMAGING TEST IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 515 FINLAND MAGNETIC RESONANCE IMAGING (MRI) IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 516 FINLAND ULTRASOUND IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 517 FINLAND CHOLANGIOPANCREATOGRAPHY IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 518 FINLAND BLOOD TEST IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 519 FINLAND TUMOR MARKER IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 520 FINLAND BIOPSY IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 521 FINLAND PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)
TABLE 522 FINLAND STAGE I IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)
TABLE 523 FINLAND STAGE II IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)
TABLE 524 FINLAND PANCREATIC CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)
TABLE 525 FINLAND EXOCRINE TUMORS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 526 FINLAND NEUROENDOCRINE TUMORS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 527 FINLAND PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 528 FINLAND INSTRUMENT-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 529 FINLAND INSTRUMENT-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 530 FINLAND INSTRUMENT-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)
TABLE 531 FINLAND PLATFORM-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 532 FINLAND PLATFORM-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 533 FINLAND PLATFORM-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)
TABLE 534 FINLAND KITS AND REAGENTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 535 FINLAND CA19-9 PANCREATIC CANCER TEST KITS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 536 FINLAND CEA PANCREATIC CANCER TEST KITS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 537 FINLAND PANCREATIC CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 538 FINLAND PANCREATIC CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 539 FINLAND SCREENING IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 540 FINLAND DIAGNOSTIC AND PREDICTIVE IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 541 FINLAND PROGNOSTIC IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 542 FINLAND RESEARCH IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 543 FINLAND PANCREATIC CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 544 FINLAND PANCREATIC CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 545 TURKEY PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 546 TURKEY IMAGING TEST IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 547 TURKEY MAGNETIC RESONANCE IMAGING (MRI) IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 548 TURKEY ULTRASOUND IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 549 TURKEY CHOLANGIOPANCREATOGRAPHY IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 550 TURKEY BLOOD TEST IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 551 TURKEY TUMOR MARKER IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 552 TURKEY BIOPSY IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 553 TURKEY PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)
TABLE 554 TURKEY STAGE I IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)
TABLE 555 TURKEY STAGE II IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)
TABLE 556 TURKEY PANCREATIC CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)
TABLE 557 TURKEY EXOCRINE TUMORS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 558 TURKEY NEUROENDOCRINE TUMORS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 559 TURKEY PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 560 TURKEY INSTRUMENT-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 561 TURKEY INSTRUMENT-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 562 TURKEY INSTRUMENT-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)
TABLE 563 TURKEY PLATFORM-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 564 TURKEY PLATFORM-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 565 TURKEY PLATFORM-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)
TABLE 566 TURKEY KITS AND REAGENTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 567 TURKEY CA19-9 PANCREATIC CANCER TEST KITS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 568 TURKEY CEA PANCREATIC CANCER TEST KITS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 569 TURKEY PANCREATIC CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 570 TURKEY PANCREATIC CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 571 TURKEY SCREENING IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 572 TURKEY DIAGNOSTIC AND PREDICTIVE IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 573 TURKEY PROGNOSTIC IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 574 TURKEY RESEARCH IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 575 TURKEY PANCREATIC CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 576 TURKEY PANCREATIC CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 577 REST OF EUROPE PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
Liste des figures
FIGURE 1 EUROPE PANCREATIC CANCER DIAGNOSTICS MARKET: SEGMENTATION
FIGURE 2 EUROPE PANCREATIC CANCER DIAGNOSTICS MARKET: DATA TRIANGULATION
FIGURE 3 EUROPE PANCREATIC CANCER DIAGNOSTICS MARKET: DROC ANALYSIS
FIGURE 4 EUROPE PANCREATIC CANCER DIAGNOSTICS MARKET: EUROPE VS REGIONAL MARKET ANALYSIS
FIGURE 5 EUROPE PANCREATIC CANCER DIAGNOSTICS MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 EUROPE PANCREATIC CANCER DIAGNOSTICS MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 EUROPE PANCREATIC CANCER DIAGNOSTICS MARKET: MARKET END USER COVERAGE GRID
FIGURE 8 EUROPE PANCREATIC CANCER DIAGNOSTICS MARKET: DBMR MARKET POSITION GRID
FIGURE 9 EUROPE PANCREATIC CANCER DIAGNOSTICS MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 EUROPE PANCREATIC CANCER DIAGNOSTICS MARKET: SEGMENTATION
FIGURE 11 GROWING AWARENESS OF PANCREATIC CANCER AND INCREASING HEALTHCARE EXPENDITURE IS EXPECTED TO DRIVE THE GROWTH OF THE EUROPE PANCREATIC CANCER DIAGNOSTICS MARKET FROM 2023 TO 2030
FIGURE 12 IMAGING TEST SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE EUROPE PANCREATIC CANCER DIAGNOSTICS MARKET IN 2023 & 2030
FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE EUROPE PANCREATIC CANCER DIAGNOSTICS MARKET
FIGURE 14 EUROPE PANCREATIC CANCER DIAGNOSTICS MARKET: BY TEST TYPE, 2022
FIGURE 15 EUROPE PANCREATIC CANCER DIAGNOSTICS MARKET: BY TEST TYPE, 2023-2030 (USD MILLION)
FIGURE 16 EUROPE PANCREATIC CANCER DIAGNOSTICS MARKET: BY TEST TYPE, CAGR (2023-2030)
FIGURE 17 EUROPE PANCREATIC CANCER DIAGNOSTICS MARKET: BY TEST TYPE, LIFELINE CURVE
FIGURE 18 EUROPE PANCREATIC CANCER DIAGNOSTICS MARKET: BY CANCER STAGES, 2022
FIGURE 19 EUROPE PANCREATIC CANCER DIAGNOSTICS MARKET: BY CANCER STAGES, 2023-2030 (USD MILLION)
FIGURE 20 EUROPE PANCREATIC CANCER DIAGNOSTICS MARKET: BY CANCER STAGES, CAGR (2023-2030)
FIGURE 21 EUROPE PANCREATIC CANCER DIAGNOSTICS MARKET: BY CANCER STAGES, LIFELINE CURVE
FIGURE 22 EUROPE PANCREATIC CANCER DIAGNOSTICS MARKET: BY TUMOR TYPE, 2022
FIGURE 23 EUROPE PANCREATIC CANCER DIAGNOSTICS MARKET: BY TUMOR TYPE, 2023-2030 (USD MILLION)
FIGURE 24 EUROPE PANCREATIC CANCER DIAGNOSTICS MARKET: BY TUMOR TYPE, CAGR (2023-2030)
FIGURE 25 EUROPE PANCREATIC CANCER DIAGNOSTICS MARKET: BY TUMOR TYPE, LIFELINE CURVE
FIGURE 26 EUROPE PANCREATIC CANCER DIAGNOSTICS MARKET: BY PRODUCT, 2022
FIGURE 27 EUROPE PANCREATIC CANCER DIAGNOSTICS MARKET: BY PRODUCT, 2023-2030 (USD MILLION)
FIGURE 28 EUROPE PANCREATIC CANCER DIAGNOSTICS MARKET: BY PRODUCT, CAGR (2023-2030)
FIGURE 29 EUROPE PANCREATIC CANCER DIAGNOSTICS MARKET: BY PRODUCT, LIFELINE CURVE
FIGURE 30 EUROPE PANCREATIC CANCER DIAGNOSTICS MARKET: BY TECHNOLOGY, 2022
FIGURE 31 EUROPE PANCREATIC CANCER DIAGNOSTICS MARKET: BY TECHNOLOGY, 2023-2030 (USD MILLION)
FIGURE 32 EUROPE PANCREATIC CANCER DIAGNOSTICS MARKET: BY TECHNOLOGY, CAGR (2023-2030)
FIGURE 33 EUROPE PANCREATIC CANCER DIAGNOSTICS MARKET: BY TECHNOLOGY, LIFELINE CURVE
FIGURE 34 EUROPE PANCREATIC CANCER DIAGNOSTICS MARKET: BY APPLICATION, 2022
FIGURE 35 EUROPE PANCREATIC CANCER DIAGNOSTICS MARKET: BY APPLICATION, 2023-2030 (USD MILLION)
FIGURE 36 EUROPE PANCREATIC CANCER DIAGNOSTICS MARKET: BY APPLICATION, CAGR (2023-2030)
FIGURE 37 EUROPE PANCREATIC CANCER DIAGNOSTICS MARKET: BY APPLICATION, LIFELINE CURVE
FIGURE 38 EUROPE PANCREATIC CANCER DIAGNOSTICS MARKET: BY END USER, 2022
FIGURE 39 EUROPE PANCREATIC CANCER DIAGNOSTICS MARKET: BY END USER, 2023-2030 (USD MILLION)
FIGURE 40 EUROPE PANCREATIC CANCER DIAGNOSTICS MARKET: BY END USER, CAGR (2023-2030)
FIGURE 41 EUROPE PANCREATIC CANCER DIAGNOSTICS MARKET: BY END USER, LIFELINE CURVE
FIGURE 42 EUROPE PANCREATIC CANCER DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, 2022
FIGURE 43 EUROPE PANCREATIC CANCER DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, 2023-2030 (USD MILLION)
FIGURE 44 EUROPE PANCREATIC CANCER DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, CAGR (2023-2030)
FIGURE 45 EUROPE PANCREATIC CANCER DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 46 EUROPE PANCREATIC CANCER DIAGNOSTICS MARKET: SNAPSHOT (2022)
FIGURE 47 EUROPE PANCREATIC CANCER DIAGNOSTICS MARKET: BY COUNTRY (2022)
FIGURE 48 EUROPE PANCREATIC CANCER DIAGNOSTICS MARKET: BY COUNTRY (2023 & 2030)
FIGURE 49 EUROPE PANCREATIC CANCER DIAGNOSTICS MARKET: BY COUNTRY (2022 & 2030)
FIGURE 50 EUROPE PANCREATIC CANCER DIAGNOSTICS MARKET: BY TEST TYPE (2023-2030)
FIGURE 51 EUROPE PANCREATIC CANCER DIAGNOSTICS MARKET: COMPANY SHARE 2022 (%)
Méthodologie de recherche
La collecte de données et l'analyse de l'année de base sont effectuées à l'aide de modules de collecte de données avec des échantillons de grande taille. L'étape consiste à obtenir des informations sur le marché ou des données connexes via diverses sources et stratégies. Elle comprend l'examen et la planification à l'avance de toutes les données acquises dans le passé. Elle englobe également l'examen des incohérences d'informations observées dans différentes sources d'informations. Les données de marché sont analysées et estimées à l'aide de modèles statistiques et cohérents de marché. De plus, l'analyse des parts de marché et l'analyse des tendances clés sont les principaux facteurs de succès du rapport de marché. Pour en savoir plus, veuillez demander un appel d'analyste ou déposer votre demande.
La méthodologie de recherche clé utilisée par l'équipe de recherche DBMR est la triangulation des données qui implique l'exploration de données, l'analyse de l'impact des variables de données sur le marché et la validation primaire (expert du secteur). Les modèles de données incluent la grille de positionnement des fournisseurs, l'analyse de la chronologie du marché, l'aperçu et le guide du marché, la grille de positionnement des entreprises, l'analyse des brevets, l'analyse des prix, l'analyse des parts de marché des entreprises, les normes de mesure, l'analyse globale par rapport à l'analyse régionale et des parts des fournisseurs. Pour en savoir plus sur la méthodologie de recherche, envoyez une demande pour parler à nos experts du secteur.
Personnalisation disponible
Data Bridge Market Research est un leader de la recherche formative avancée. Nous sommes fiers de fournir à nos clients existants et nouveaux des données et des analyses qui correspondent à leurs objectifs. Le rapport peut être personnalisé pour inclure une analyse des tendances des prix des marques cibles, une compréhension du marché pour d'autres pays (demandez la liste des pays), des données sur les résultats des essais cliniques, une revue de la littérature, une analyse du marché des produits remis à neuf et de la base de produits. L'analyse du marché des concurrents cibles peut être analysée à partir d'une analyse basée sur la technologie jusqu'à des stratégies de portefeuille de marché. Nous pouvons ajouter autant de concurrents que vous le souhaitez, dans le format et le style de données que vous recherchez. Notre équipe d'analystes peut également vous fournir des données sous forme de fichiers Excel bruts, de tableaux croisés dynamiques (Fact book) ou peut vous aider à créer des présentations à partir des ensembles de données disponibles dans le rapport.
